UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 29, 2025
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)
66 Hudson Boulevard East, New York, New York 10001-2192
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE/27New York Stock Exchange
2.875% Notes due 2029
PFE/29
New York Stock Exchange
3.250% Notes due 2032
PFE/32
New York Stock Exchange
3.875% Notes due 2037
PFE/37A
New York Stock Exchange
4.250% Notes due 2045
PFE/45
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes Nox
At July 30, 2025, 5,685,550,500 shares of the issuer s voting common stock were outstanding.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Comprehensive Income
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Equity
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements
10
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
34
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
54
Item 4.
Controls and Procedures
54
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
54
Item 1A.
Risk Factors
54
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
54
Item 3.
Defaults Upon Senior SecuritiesN/A
Item 4.
Mine Safety DisclosuresN/A
Item 5.
Other Information
54
Item 6.
Exhibits
55
Signature
55
N/A = Not Applicable
DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 25, 2025 and May 26, 2024, and for U.S. subsidiaries is as of and for the three and six months ended June 29, 2025 and June 30, 2024. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2024 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
Indicates calculation not meaningful or results are greater than 100%
2024 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2024
340B Program
340B Drug Pricing Program
3SBio
3SBio, Inc. and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd.
AbbVie
AbbVie Inc.
AI
artificial intelligence
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
Blackstone
Blackstone Life Sciences
BMSBristol-Myers Squibb Company
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
CMS
Centers for Medicare & Medicaid Services
CODMChief Operating Decision Maker
Comirnaty(a)
Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula; Comirnaty (COVID-19 Vaccine, mRNA) 2025-2026 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; Comirnaty JN.1 and Comirnaty KP.2.
COVID-19novel coronavirus disease of 2019
Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Central Europe, Canada, Australia, Eastern Europe, Scandinavian countries, South Korea, New Zealand and Finland
EMAEuropean Medicines Agency
Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe (excluding the Balkans), Africa, the Middle East and Turkey
EPS
earnings per share
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended June 29, 2025
GAAPU.S. Generally Accepted Accounting Principles
GSKGSK plc
HaleonHaleon plc
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
HRR
homologous recombination repair
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSU.S. Internal Revenue Service
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
mCRCmetastatic colorectal cancer
mCRPCmetastatic castration-resistant prostate cancer
mCSPCmetastatic castration-sensitive prostate cancer
MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations
MDLMulti-District Litigation
Medicare Part B
a medical insurance plan that helps cover medically necessary services, outpatient care, and preventative services for people with Medicare
Medicare Part D
a prescription drug coverage program for people with Medicare
MeridianMeridian Medical Technologies, Inc.
Moody s
Moody s Ratings (formerly Moody s Investors Service)
mRNAmessenger ribonucleic acid
NDA
New Drug Application
nmCRPCnon-metastatic castration-resistant prostate cancer
nmCSPC
non-metastatic castration-sensitive prostate cancer
NSCLCnon-small cell lung cancer
OBBBA
One Big Beautiful Bill Act
ODToral disintegrating tablet
Ono
Ono Pharmaceutical Co., Ltd.
OTCover-the-counter
Paxlovid(a)
an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)
PC1Pfizer CentreOne
PharmaciaPharmacia LLC (formerly Pharmacia Corporation)
Pierre Fabre
Pierre Fabre Medicament SAS
PNIF
Pfizer Netherlands International Finance B.V. (a wholly-owned finance subsidiary of Pfizer)
Prevnar familyIncludes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)
PsApsoriatic arthritis
QTDQuarter-to-date or three months ended
RArheumatoid arthritis
R&Dresearch and development
RSVrespiratory syncytial virus
S&PS&P Global (formerly Standard & Poor s)
SeagenSeagen Inc. and its subsidiaries
SECU.S. Securities and Exchange Commission
SI&A
Selling, informational and administrative expenses
Takeda
Takeda Pharmaceutical Company Limited
UCulcerative colitis
U.K.United Kingdom
U.S.United States
ViiVViiV Healthcare Limited
Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac
YTDYear-to-date or six months ended
(a)Certain uses of Paxlovid and COVID-19 vaccines from BioNTech and Pfizer have not been approved or licensed by the FDA. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Emergency uses of COVID-19 vaccines from Pfizer and BioNTech, including Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula), have been authorized for emergency use by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months EndedSix Months Ended
(MILLIONS, EXCEPT PER SHARE DATA)June 29,
2025June 30,
2024June 29,
2025June 30,
2024
Revenues:
Product revenues
$11,954 $10,871 $23,248 $23,314
Alliance revenues
2,273 2,067 4,386 4,240
Royalty revenues
426 345 734 608
Total revenues14,653 13,283 28,367 28,162
Costs and expenses:
Cost of sales(a)
3,778 3,300 6,624 6,679
Selling, informational and administrative expenses(a)
3,415 3,717 6,446 7,212
Research and development expenses(a)
2,482 2,696 4,685 5,189
Acquired in-process research and development expenses2 6 11 6
Amortization of intangible assets1,211 1,307 2,421 2,615
Restructuring charges and certain acquisition-related costs(18)1,254 660 1,356
Other (income)/deductions net739 1,107 1,692 1,787
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)
3,044 (103)5,828 3,318
Provision/(benefit) for taxes on income/(loss)
141 (134)(48)159
Income from continuing operations2,903 31 5,876 3,159
Discontinued operations net of tax25 17 25 12
Net income before allocation to noncontrolling interests
2,928 48 5,901 3,171
Less: Net income attributable to noncontrolling interests18 7 24 15
Net income attributable to Pfizer Inc. common shareholders
$2,910 $41 $5,877 $3,156
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
$0.51 $0.01 $1.03 $0.56
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
$0.51 $0.01 $1.03 $0.56
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
$0.51 $0.01 $1.03 $0.55
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
$0.51 $0.01 $1.03 $0.55
Weighted-average shares basic5,685 5,666 5,680 5,662
Weighted-average shares diluted5,706 5,696 5,708 5,696
(a)Exclusive of amortization of intangible assets.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months EndedSix Months Ended
(MILLIONS)June 29,
2025June 30,
2024June 29,
2025June 30,
2024
Net income before allocation to noncontrolling interests$2,928 $48 $5,901 $3,171
Foreign currency translation adjustments, net127 (70)(430)70
Unrealized holding gains/(losses) on derivative financial instruments, net(273)127 (395)343
Reclassification adjustments for (gains)/losses included in net income(a)
(106)(147)(419)(159)
(379)(21)(814)184
Unrealized holding gains/(losses) on available-for-sale securities, net166 (25)135 (77)
Reclassification adjustments for (gains)/losses included in net income(b)
(83)100 72 86
82 74 207 9
Reclassification adjustments related to amortization of prior service costs and other, net(24)(28)(55)(56)
Reclassification adjustments related to curtailments of prior service costs and other, net(11) (44)
(35)(28)(99)(56)
Other comprehensive income/(loss), before tax(204)(44)(1,136)207
Tax provision/(benefit) on other comprehensive income/(loss)(347)22 (538)76
Other comprehensive income/(loss) before allocation to noncontrolling interests$143 $(67)$(598)$131
Comprehensive income/(loss) before allocation to noncontrolling interests$3,071 $(19)$5,303 $3,302
Less: Comprehensive income/(loss) attributable to noncontrolling interests18 (2)22 1
Comprehensive income/(loss) attributable to Pfizer Inc.$3,053 $(17)$5,282 $3,302
(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions net.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)June 29,
2025December 31, 2024
(Unaudited)
Assets
Cash and cash equivalents$1,638 $1,043
Short-term investments11,611 19,434
Trade accounts receivable, net of allowance for doubtful accounts: 2025 $439; 2024 $438
12,078 11,463
Inventories11,669 10,851
Current tax assets4,016 3,314
Other current assets2,690 4,253
Total current assets43,703 50,358
Equity-method investments224 217
Long-term investments1,896 2,010
Property, plant and equipment, net of accumulated depreciation: 2025 $17,268; 2024 $16,483
18,776 18,393
Identifiable intangible assets, net
52,702 55,411
Goodwill68,997 68,527
Noncurrent deferred tax assets and other noncurrent tax assets10,343 8,662
Other noncurrent assets9,455 9,817
Total assets$206,095 $213,396
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2025 $4,246; 2024 $3,747
$4,295 $6,946
Trade accounts payable5,166 5,633
Dividends payable2,445 2,437
Income taxes payable3,675 2,910
Accrued compensation and related items2,447 3,838
Deferred revenues1,123 1,511
Other current liabilities18,575 19,720
Total current liabilities37,726 42,995
Long-term debt57,502 57,405
Pension and postretirement benefit obligations2,130 2,115
Noncurrent deferred tax liabilities2,481 2,122
Other taxes payable3,313 6,112
Other noncurrent liabilities13,931 14,150
Total liabilities117,083 124,899
Commitments and Contingencies
Common stock481 480
Additional paid-in capital94,053 93,603
Treasury stock(115,010)(114,763)
Retained earnings117,609 116,725
Accumulated other comprehensive loss(8,438)(7,842)
Total Pfizer Inc. shareholders equity88,695 88,203
Equity attributable to noncontrolling interests317 294
Total equity89,012 88,497
Total liabilities and equity$206,095 $213,396
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, March 31, 20259,620 $481 $93,856 (3,935)$(115,008)$119,590 $(8,581)$90,338 $299 $90,637
Net income/(loss)
2,910 2,910 18 2,928
Other comprehensive income/(loss), net of tax
143 143 143
Cash dividends declared, per share: $0.86
Common stock(4,890)(4,890)(4,890)
Share-based payment transactions 197 (2)(1)195 195
Other (1)(1) (1)
Balance, June 29, 20259,620 $481 $94,053 (3,935)$(115,010)$117,609 $(8,438)$88,695 $317 $89,012
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, March 31, 20249,592 $480 $92,997 (3,925)$(114,755)$121,318 $(7,758)$92,282 $276 $92,558
Net income/(loss)
41 41 7 48
Other comprehensive income/(loss), net of tax(58)(58)(9)(67)
Cash dividends declared, per share: $0.84
Common stock (4,760)(4,760)(4,760)
Share-based payment transactions 200 (2)(2)196 196
Other
Balance, June 30, 20249,592 $480 $93,197 (3,925)$(114,757)$116,596 $(7,816)$87,700 $275 $87,975
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20259,593 $480 $93,603 (3,926)$(114,763)$116,725 $(7,842)$88,203 $294 $88,497
Net income
5,877 5,877 24 5,901
Other comprehensive income/(loss), net of tax(596)(596)(3)(598)
Cash dividends declared, per share: $0.86
Common stock(4,890)(4,890)(4,890)
Share-based payment transactions28 1 450 (9)(246)(104)101 101
Other 2 2
Balance, June 29, 20259,620 $481 $94,053 (3,935)$(115,010)$117,609 $(8,438)$88,695 $317 $89,012
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20249,562 $478 $92,631 (3,916)$(114,487)$118,353 $(7,961)$89,014 $274 $89,288
Net income
3,156 3,156 15 3,171
Other comprehensive income/(loss), net of tax145 145 (14)131
Cash dividends declared, per share: $0.84
Common stock (4,760)(4,760)(4,760)
Share-based payment transactions30 1 566 (10)(270)(153)144 144
Other
Balance, June 30, 20249,592 $480 $93,197 (3,925)$(114,757)$116,596 $(7,816)$87,700 $275 $87,975
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(MILLIONS)June 29,
2025June 30,
2024
Operating Activities
Net income before allocation to noncontrolling interests$5,901 $3,171
Discontinued operations net of tax25 12
Net income from continuing operations before allocation to noncontrolling interests5,876 3,159
Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
Depreciation and amortization3,243 3,467
Asset write-offs and impairments498 431
Deferred taxes(935)(1,224)
Share-based compensation expense373 426
Benefit plan contributions in excess of expense/income(334)(338)
Other adjustments, net(61)260
Other changes in assets and liabilities, net of acquisitions and divestitures(6,908)(6,871)
Net cash provided by/(used in) operating activities1,753 (691)
Investing Activities
Purchases of property, plant and equipment(1,182)(1,341)
Purchases of short-term investments(6,085)(1,254)
Proceeds from redemptions/sales of short-term investments10,500 1,712
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(2,668)3,538
Purchases of long-term investments(86)(108)
Proceeds from redemptions/sales of long-term investments145 312
Proceeds from sales of investment in Haleon(a)
6,311 3,491
Other investing activities, net288 (18)
Net cash provided by/(used in) investing activities7,225 6,332
Financing Activities
Proceeds from short-term borrowings 6,014
Payments on short-term borrowings(2,199)(4,852)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
(903)(1,101)
Proceeds from issuance of long-term debt3,687
Payments on long-term debt(3,750)(2,250)
Cash dividends paid(4,882)(4,752)
Other financing activities, net(377)(449)
Net cash provided by/(used in) financing activities(8,423)(7,390)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
34 (46)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents588 (1,794)
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,107 2,917
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,694 $1,123
Supplemental Cash Flow Information
Cash paid/(received) during the period for:
Income taxes
$3,493 $2,686
Interest paid
1,483 1,553
Interest rate hedges29 (2)
(a) See Note 7A.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2024 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2024 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 25, 2025 and May 26, 2024, and for U.S. subsidiaries is as of and for the three and six months ended June 29, 2025 and June 30, 2024.
We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See Note 13A.
B. Revenues and Trade Accounts Receivable
Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)June 29,
2025December 31, 2024
Reserve against Trade accounts receivable, net of allowance for doubtful accounts
$1,589 $1,627
Other current liabilities:
Accrued rebates8,692 7,195
Other accruals644 972
Other noncurrent liabilities
742 1,029
Total accrued rebates and other sales-related accruals$11,667 $10,822
Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
During the three and six months ended June 29, 2025 and June 30, 2024, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2024 Form 10-K.
Note 2. Research and Development Arrangement
Research and Development Funding Arrangement with Blackstone In March 2025, we entered into an arrangement with Blackstone under which we will receive up to a total of $326 million in 2025 through 2028 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $277 million contingent upon the successful results of the clinical trials and payable to Blackstone over a period of one to three years. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $897 million in
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
total based on achievement of certain levels of cumulative applicable net sales and payable to Blackstone over a period of five to seven years. The net present value of the approval-based milestone payments and sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Accretion of interest on the liabilities to pay Blackstone will be recognized as interest expense in Other (income)/deductions net.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Realigning Our Cost Base Program
In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. We expect costs associated with this initial part of the program to continue primarily through 2025 and to total approximately $3.1 billion, primarily representing cash expenditures for severance, exit and implementation costs as well as non-cash asset write downs of which $2.4 billion is associated with our Biopharma segment.
In the second quarter of 2025, we identified additional productivity opportunities to further reduce costs primarily in SI&A, driven in large part by enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs associated with the additional productivity opportunities to be incurred through 2027 and to total approximately $1.6 billion, primarily representing cash expenditures for severance, digital enablement and implementation, of which $700 million is associated with our Biopharma segment.
In connection with our efforts to simplify the structure and sharpen the focus of our R&D organization, in the first quarter of 2025, we expanded this program after having identified additional opportunities to drive improvements in productivity and operational efficiencies through enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment. The majority of these costs were recorded in the first quarter of 2025, with cash outlays expected primarily in 2025 and 2026.
We expect costs associated with all three components of this program to total approximately $5.3 billion of which $3.7 billion is associated with the Biopharma segment.
From the start of this program through June 29, 2025, we incurred total costs under this program of $3.5 billion, of which $2.7 billion is associated with our Biopharma segment (including $2.5 billion of restructuring charges).
B. Manufacturing Optimization Program
In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies, and we expect costs for this first phase to total approximately $1.4 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. From the start of this program through June 29, 2025, we incurred costs under this program of $850 million, substantially all of which is restructuring costs for our Biopharma segment. These costs were recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026.
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
C. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months EndedSix Months Ended
(MILLIONS)June 29,
2025June 30,
2024June 29,
2025June 30,
2024
Restructuring charges/(credits):
Employee terminations$(148)$1,014 $236 $984
Asset impairments44 41 217 66
Exit costs
30 49 94 63
Restructuring charges/(credits)(a)
(74)1,104 547 1,114
Transaction costs(b)
Integration costs and other(c)
56 150 113 237
Restructuring charges and certain acquisition-related costs(18)1,254 660 1,356
Net periodic benefit costs/(credits) recorded in Other (income)/deductions net
(9)2 (68)5
Additional depreciation asset restructuring recorded in our condensed consolidated statements of operations as follows(d):
Cost of sales3 1 7 5
Selling, informational and administrative expenses 3 3
Total additional depreciation asset restructuring
4 4 7 8
Implementation costs recorded in our condensed consolidated statements of operations as follows(e):
Cost of sales26 49 46 65
Selling, informational and administrative expenses14 36 20 65
Research and development expenses39 20 62 33
Total implementation costs78 105 128 163
Total costs associated with acquisitions and cost-reduction/productivity initiatives$54 $1,364 $727 $1,532
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) credits of $406 million for the three months ended June 29, 2025 (including credits of $408 million for our Manufacturing Optimization Program and $25 million for our Realigning our Cost Base Program), (ii) charges of $211 million for the six months ended June 29, 2025 (including charges of $562 million for our Realigning our Cost Base Program and credits of $412 million for our Manufacturing Optimization Program) and (iii) charges of $1.1 billion for both the three and six months ended June 30, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program for both periods presented and credits of $113 million for the three months and $199 million for the six months ended June 30, 2024 for our Realigning our Cost Base Program). For all periods presented, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
(b)Represents external costs for banking, legal, accounting and other similar services.
(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
CostsAsset
Impairment
ChargesExit CostsAccrual
Balance, December 31, 2024(a)
$2,046 $ $74 $2,120
Provision
236 217 94 547
Utilization and other(b)
(494)(217)30 (681)
Balance, June 29, 2025(c)
$1,788 $ $198 $1,986
(a)Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
(c)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($685 million).
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 4. Other (Income)/Deductions Net
Components of Other (income)/deductions net include:
Three Months EndedSix Months Ended
(MILLIONS)June 29,
2025June 30,
2024June 29,
2025June 30,
2024
Interest income$(156)$(130)$(299)$(259)
Interest expense654 778 1,308 1,568
Net interest expense(a)
498 648 1,009 1,310
Net (gains)/losses recognized during the period on equity securities(b)
(75)342 295 317
Net periodic benefit costs/(credits) other than service costs(101)(106)(260)(209)
Certain legal matters, net(c)
422 169 564 377
Certain asset impairments(d)
93 240 317 349
Haleon equity method (income)/loss
(40) 48
Other, net(e)
(97)(146)(233)(404)
Other (income)/deductions net$739 $1,107 $1,692 $1,787
(a)The decrease in net interest expense in the second quarter and first six months of 2025 reflects (i) a decrease in interest expense primarily driven by a reduction in commercial paper outstanding and (ii) an increase in interest income due to higher total average investment asset balance compared to 2024.
(b)The net losses in the first six months of 2025 include, among other things, a net loss of $144 million related to our investment in Haleon, composed of unrealized losses of $1.0 billion, partially offset by $900 million in realized gains on the sales of our remaining investment.
(c)The amounts for the second quarter and first six months of 2025 primarily include certain product liability and other legal expenses. The amounts for the second quarter and first six months of 2024 primarily included certain product liability expenses related to products discontinued and/or divested by Pfizer.
(d)The first six months of 2025 primarily includes an intangible asset impairment charge associated with our Biopharma segment of $210 million for KRAS G12D, a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner. The amounts for the second quarter and first six months of 2024 included a $240 million intangible asset impairment charge, associated with our Biopharma segment that represented IPR&D related to a Phase 3 study for the treatment of DMD, which reflected unfavorable clinical trial results.
(e)The first six months of 2025 primarily include dividend income of $111 million from our investment in ViiV. The first six months of 2024 included, among other things, a $150 million realized gain on the partial sale of our investment in Haleon and dividend income of $135 million from our investment in ViiV.
Additional information about the intangible assets that were impaired during 2025 follows:
Six Months Ended
Fair Value(a)
June 29, 2025
(MILLIONS)AmountLevel 1Level 2Level 3Impairment
Indefinite-lived licensing agreement(b)
$ $ $ $ $210
IPR&D(b), (c)
590 590 93
Developed technology rights(b)
14
Total
$590 $ $ $590 $317
(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See Note 1E in our 2024 Form 10-K.
(b)Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
(c)See Note 9.
Note 5. Tax Matters
A. Taxes on Income/(Loss) from Continuing Operations
Our effective tax rate for continuing operations was 4.6% for the second quarter of 2025, compared to 130.2% for the second quarter of 2024, and was (0.8)% for the first six months of 2025, compared to 4.8% for the first six months of 2024. The lower effective tax rate for the second quarter of 2025, compared to the second quarter of 2024, was primarily due to a favorable change in the jurisdictional mix of earnings. The negative and lower effective tax rate for the first six months of 2025, compared to the first six months of 2024, was primarily due to tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years.
13
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The seventh annual installment was paid by its April 15, 2025 due date. The eighth and final annual installment is due April 15, 2026 and is reported in current Income taxes payable as of June 29, 2025. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.
See Note 5A in our 2024 Form 10-K for information on our cash paid for income taxes, net of refunds.
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. Tax years 2019-2022 are under audit. Tax years 2023-2025 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2014.
See Note 5D in our 2024 Form 10-K.
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months EndedSix Months Ended
(MILLIONS)June 29,
2025June 30,
2024June 29,
2025June 30,
2024
Foreign currency translation adjustments, net(a)
$(269)$18 $(372)$42
Unrealized holding gains/(losses) on derivative financial instruments, net(48)26 (82)70
Reclassification adjustments for (gains)/losses included in net income
(32)(23)(87)(26)
(80)3 (169)44
Unrealized holding gains/(losses) on available-for-sale securities, net21 (3)17 (9)
Reclassification adjustments for (gains)/losses included in net income
(10)12 9 11
10 9 26 1
Reclassification adjustments related to amortization of prior service costs and other, net(6)(9)(13)(13)
Reclassification adjustments related to curtailments of prior service costs and other, net(1)1 (10)1
(7)(7)(23)(12)
Tax provision/(benefit) on other comprehensive income/(loss)$(347)$22 $(538)$76
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, January 1, 2025
$(7,984)$57 $(106)$191 $(7,842)
Other comprehensive income/(loss)(b)
(56)(645)181 (76)(596)
Balance, June 29, 2025$(8,040)$(589)$75 $115 $(8,438)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.
14
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 7. Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
June 29, 2025December 31, 2024
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair value(a)
$1,687 $ $1,687 $7,848 $6,456 $1,392
Available-for-sale debt securities:
Government and agency non-U.S.
5,640 5,640 6,855 6,855
Government and agency U.S.
2,290 2,290 2,853 2,853
Corporate and other
1,595 1,595 1,173 1,173
9,525 9,525 10,881 10,881
Total short-term investments11,212 11,212 18,729 6,456 12,273
Other current assets
Derivative assets:
Foreign exchange contracts
281 281 1,056 1,056
Total other current assets281 281 1,056 1,056
Long-term investments
Equity securities with readily determinable fair values(b)
1,118 1,118 1,246 1,246
Available-for-sale debt securities:
Government and agency non-U.S.
1 1
1 1
Total long-term investments1,119 1,118 1 1,246 1,246
Other noncurrent assets
Derivative assets:
Interest rate contracts
59 59 13 13
Foreign exchange contracts
27 27 447 447
Total derivative assets86 86 460 460
Insurance contracts(c)
923 923 875 875
Total other noncurrent assets1,009 1,009 1,335 1,335
Total assets$13,621 $1,118 $12,503 $22,366 $7,701 $14,665
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$18 $ $18 $28 $ $28
Foreign exchange contracts
681 681 217 217
Total other current liabilities698 698 245 245
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts229 229 397 397
Foreign exchange contracts
984 984 723 723
Total other noncurrent liabilities1,213 1,213 1,121 1,121
Total liabilities$1,911 $ $1,911 $1,366 $ $1,366
(a)Includes money market funds primarily invested in U.S. Treasury and government debt. As of December 31, 2024, short-term equity securities included our investment in Haleon of $6.5 billion. In the first quarter of 2025, we sold the remaining portion of our investment in Haleon for $6.3 billion.
(b)Long-term equity securities of $131 million as of June 29, 2025 and $133 million as of December 31, 2024 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $58 billion as of June 29, 2025 and $57 billion as of December 31, 2024. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $55 billion as of June 29, 2025 and $54 billion as of December 31, 2024.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of June 29, 2025 and December 31, 2024. The fair value measurements of our held-to-maturity debt securities and short-term
15
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term, Long-Term and Equity-Method Investments
The following summarizes our investments by classification type:
(MILLIONS)June 29,
2025 December 31, 2024
Short-term investments
Equity securities with readily determinable fair values
$1,687 $7,848
Available-for-sale debt securities9,525 10,881
Held-to-maturity debt securities399 705
Total Short-term investments$11,611 $19,434
Long-term investments
Equity securities with readily determinable fair values(a)
$1,118 $1,246
Available-for-sale debt securities1
Held-to-maturity debt securities48 45
Private equity securities at cost(a)
729 719
Total Long-term investments$1,896 $2,010
Equity-method investments224 217
Total long-term investments and equity-method investments$2,120 $2,228
Held-to-maturity cash equivalents$390 $184
(a)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
June 29, 2025December 31, 2024
Gross Unrealized Maturities (in Years)
Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency non-U.S.
$5,556 $85 $(1)$5,640 $5,640 $1 $ $6,970 $8 $(123)$6,855
Government and agency U.S.
2,290 2,290 2,290 2,853 2,853
Corporate and other1,593 2 1,595 1,595 1,179 (6)1,173
Held-to-maturity debt securities
Time deposits and other
832 832 789 9 34 697 697
Government and agency non-U.S.
5 5 5 237 237
Total debt securities$10,276 $87 $(1)$10,362 $10,314 $14 $34 $11,935 $8 $(129)$11,814
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:
Three Months EndedSix Months Ended
(MILLIONS)June 29,
2025June 30,
2024June 29,
2025June 30,
2024
Net (gains)/losses recognized during the period on equity securities(a)
$(75)$342 $295 $317
Less: Net (gains)/losses recognized during the period on equity securities sold during the period(10)(2)(934)(216)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)
$(65)$344 $1,230 $533
(a)Reported in Other (income)/deductions net. See Note 4.
16
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
(b)Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of June 29, 2025, there were cumulative impairments and downward adjustments of $435 million and upward adjustments of $239 million. Impairments, downward and upward adjustments were not material to our operations in the second quarters and first six months of 2025 and 2024.
C. Short-Term Borrowings
Short-term borrowings include:
(MILLIONS) June 29,
2025 December 31, 2024
Commercial paper, principal amount
$ $2,453
Current portion of long-term debt, principal amount4,250 3,750
Other short-term borrowings, principal amount(a)
50 755
Total short-term borrowings, principal amount
4,300 6,957
Net unamortized discounts, premiums and debt issuance costs(4)(12)
Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted